Old name, new purpose: why we’ve gone back to RNID

Translational Grant

The Translational Grant aims to support and accelerate the translation of research discoveries into potential new treatments to protect and regenerate hearing and /or silence tinnitus. It funds projects at both academic institutions and small/medium enterprises in any country. 

RNID and Fondation Pour l’Audition are partnering to co-fund translational grants.

Why supporting the development of treatments for hearing loss and tinnitus is important

There are almost half a billion people in the world with disabling hearing loss and 1.1 billion young people (aged between 12 and 35 years old) are at risk of losing their hearing due to recreational noise (WHO, 2018).

The evidence of the link between hearing loss and debilitating conditions like dementia is strengthening (Livingston, G et al (2017) The Lancet).

In the UK, around 1 in 8 people has tinnitus. However, there are currently no registered treatments that protect and/or restore hearing or silence tinnitus.

We request translational research proposals that will advance the development of small molecule, gene or cell-based therapeutics for the treatment of hearing disorders, including tinnitus.

We seek to support:

  • research with a strong commercial potential that is likely to attract follow-on funding at the conclusion of the grant
  • studies that will facilitate and enable the progression of promising basic research towards testing in clinical trials.

Summary of grant

  • Duration: Up to three years
  • Eligibility: Applicants may be from any country and may be from academic institutions and small/medium enterprises (SMEs)
  • Value: Up to £100,000 per year (note that as a charity, it is our policy not to fund any indirect costs or the salaries of permanent employees)
  • Expression of interest deadline: 9 April 2021 (5pm GMT)
  • Full application deadline (by invitation only): 11 June 2021 (5pm GMT)
  • Funding decisions deadline: November/December 2021

In the last round of funding, we received 17 expressions of interest. Of these, nine applicants were invited to submit a full application, following which, 2 grants were awarded.

Applications that will and won’t be accepted

Applications can include:

  • Studies which will enable lead optimisation and/or candidate selection.
  • Pharmacokinetics/Pharmacodynamics (PKPD) studies.
  • Safety/toxicology studies.
  • Drug repositioning/repurposing (applications must contain preliminary data supporting the proposed approach)
  • Validation of therapeutic targets for the treatment of hearing loss or tinnitus (applications must contain preliminary data supporting the proposed approach).
  • Studies to strengthen confidence that a target or therapeutic approach will be applicable to human hearing loss or tinnitus.
  • Identification/validation of methods or outcomes that could be used for one or more of the following: Patient selection/stratification for clinical trials; Robust measurement of treatment responses in clinical trials.

These studies must support the development of a specific therapeutic. General research into outcome measures not aligned to a specific therapeutic should be submitted to other grant schemes of RNID (for example Discovery Research Grant) and Fondation Pour l’ Audition.

Applications will not be accepted in the following areas:

  • Basic research into the causes and underpinning biology of hearing loss and tinnitus.
  • The development of devices or software.
  • The optimization of current clinical protocols.
  • Health service studies.

Application procedure

This grant application will follow a two-stage process:

  1. Expression of Interest: All applicants must submit an Expression of Interest. The purpose of the Expression of Interest is to obtain enough information on the proposed project to enable us to understand how well the proposal aligns with the criteria of the Translational. Applicants with proposals meeting the criteria of the Translational will be invited to submit a full application.
  2. Full Application: Applications that successfully complete the Expression of Interest stage will be invited to submit a Full Application.


In order to protect the confidentiality of the information shared with us by the applicants everyone involved in the review process of any Translational grant application is asked to abide by our code of conduct and to sign a Reviewer Agreement with confidentiality clauses.

Stages of the application procedure

1. Expression of interest

Expressions of interest are open entry. 

2. Assessment

Additional information may be requested in order to determine if applications meet the criteria of the scheme. 

3. Full application

Full application (by invitation only), following the successful outcome of the EOI stage.

4. External assessment

All full applications are sent for external peer review by 2 to 3 experts in the field, who are asked to rate the scientific value, feasibility and translational potential of the project. Applicants will have the opportunity to respond to the reviewer’s feedback.

5. Review panel assessment

Full applications and expert reviews are considered by the Translational Funding Review Panel for scientific approach, commercial and/or translational potential.

At this stage abstracts are sent to the TRIH Research Partners (prior to this, applicants have the opportunity to list any TRIH Research Partners they do not wish to see their application). TRIH partners are not involved in the review process but have the opportunity to express interest in providing support to projects.

6. Funding 

Projects are ranked competitively and funding is awarded to the top-rated projects. 

How to apply

Use the form below to submit your expression of interest.

Applicants whose proposals meet the scheme’s criteria will be invited to submit a full application. See the document below for full details.

A reminder that these studies must support the development of a specific therapeutic. General research into outcome measures not aligned to a specific therapeutic should be submitted to other grant schemes of RNID (for example Discovery Research Grant) and Fondation Pour l’ Audition.

Review panel

  • Dr Trevor Perrior (Drug Discovery Consultant)
  • Dr Klaus Mendla (Auditus Business Consulting)
  • Dr Michael Kyriakides (Syncona Investment Management Ltd)
  • Dr Anna Kenyon (Patient representative)
  • Mr Peter Monksfield (University Hospitals Birmingham)
  • Dr Louise Jones (UKRI MRC)
  • Professor Marcelo Rivolta (University of Sheffield)
  • Selected members of the Scientific Committee of the Fondation Pour l’Audition

Additional panel members may be recruited.

Project management and reporting

Successful TRIH grants require annual scientific and financial reporting. This ensures that the milestones are met and the project is successfully completed.

Europe PubMed Central (Europe PMC) and open access publications

RNID is a member of the Europe PMC Funders’ Group. We support open access publications and require RNID grant holders to make their publications open access.

Read our open access publication policy for more information and visit the Europe PMC website.

For more information

Please get in touch if you would like more information about the Translational Research grant.

020 3227 6020